The price of Augmedix Inc (NASDAQ: AUGX) closed at $4.02 in the last session, down -1.71% from day before closing price of $4.09. In other words, the price has decreased by -$0.0700 from its previous closing price. On the day, 558815 shares were traded.
Ratios:
We take a closer look at AUGX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.41 and its Current Ratio is at 2.41. In the meantime, Its Debt-to-Equity ratio is 1.11 whereas as Long-Term Debt/Eq ratio is at 0.83.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Evercore ISI on December 15, 2023, initiated with a In-line rating and assigned the stock a target price of $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 28 ’24 when Shakil Ian sold 31,994 shares for $4.06 per share. The transaction valued at 129,851 led to the insider holds 187,666 shares of the business.
Ginocchio Paul bought 10,000 shares of AUGX for $48,500 on Nov 22 ’23. The CHIEF FINANCIAL OFFICER now owns 128,000 shares after completing the transaction at $4.85 per share. On Nov 20 ’23, another insider, Redmile Group, LLC, who serves as the Director of the company, bought 750,000 shares for $4.00 each. As a result, the insider paid 3,000,000 and bolstered with 16,404,017 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUGX now has a Market Capitalization of 195.93M and an Enterprise Value of 175.56M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.37 while its Price-to-Book (P/B) ratio in mrq is 8.38. Its current Enterprise Value per Revenue stands at 3.91 whereas that against EBITDA is -11.20.
Stock Price History:
The Beta on a monthly basis for AUGX is 0.34, which has changed by 139.18% over the last 52 weeks, in comparison to a change of 28.14% over the same period for the S&P500. Over the past 52 weeks, AUGX has reached a high of $6.25, while it has fallen to a 52-week low of $1.50. The 50-Day Moving Average of the stock is 4.2775, while the 200-Day Moving Average is calculated to be 4.7986.
Shares Statistics:
According to the various share statistics, AUGX traded on average about 385.90K shares per day over the past 3-months and 531.41k shares per day over the past 10 days. A total of 48.61M shares are outstanding, with a floating share count of 43.44M. Insiders hold about 10.87% of the company’s shares, while institutions hold 75.16% stake in the company. Shares short for AUGX as of Mar 15, 2024 were 747.99k with a Short Ratio of 1.94, compared to 728.85k on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.54% and a Short% of Float of 2.73%.
Earnings Estimates
The company has 3 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.14 for the current quarter, with a high estimate of -$0.11 and a low estimate of -$0.17, while EPS last year was -$0.14. The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.11 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.44 and -$0.58 for the fiscal current year, implying an average EPS of -$0.52. EPS for the following year is -$0.38, with 3 analysts recommending between -$0.29 and -$0.44.
Revenue Estimates
According to 4 analysts, the current quarter’s revenue is expected to be $13.4M. It ranges from a high estimate of $13.43M to a low estimate of $13.37M. As of the current estimate, Augmedix Inc’s year-ago sales were $9.63M, an estimated increase of 39.20% from the year-ago figure.
A total of 4 analysts have provided revenue estimates for AUGX’s current fiscal year. The highest revenue estimate was $61.45M, while the lowest revenue estimate was $60.79M, resulting in an average revenue estimate of $61.14M. In the same quarter a year ago, actual revenue was $44.85M, up 36.30% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $84.62M in the next fiscal year. The high estimate is $86M and the low estimate is $83.39M. The average revenue growth estimate for next year is up 38.40% from the average revenue estimate for this year.
